Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
27.24 USD 1.58 ( 6.16%)
Last update at 2026-11-18T20:55:00Z
VOLUME
852086
Market Cap
1606.94M

Momentum Score

…

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
25.34
Low
27.99
High
52 Week Price Range
20.76
Low
59.24
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
25.66
Dividend Yield
-
Revenue TTM
188.48M
Revenue Per Share
2.62
Gross Profit TTM
101.02M
Debt / Equity
0.23
ROE
-25.93%
Net Debt
-33.18M
ROCE
-22.28%
Diluted EPS TTM
-2.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -149.13M -100.81M -26.29M -25.97M -28.35M
Minority interest 0.00M -0.83M -2.17M 0.04M 0.04M
Net income -149.19M -101.22M -26.64M -25.68M -28.43M
Selling general administrative 90.83M 64.01M 41.90M 27.04M 18.55M
Selling and marketing expenses 30.64M 22.15M 17.80M 21.36M 17.83M
Gross profit 101.02M 65.62M 63.47M 49.09M 42.94M
Reconciled depreciation 4.34M 2.85M 3.66M 3.64M 2.89M
Ebit -149.12M -111.44M -60.92M -38.72M -27.16M
Ebitda -144.78M -119.95M -85.52M -45.00M -24.26M
Depreciation and amortization 4.34M -8.51M -24.61M -6.28M 2.89M
Non operating income net other - 10.63M 34.62M - -
Operating income -149.12M -111.44M -60.92M -38.72M -27.97M
Other operating expenses 327.77M 249.37M 169.01M 124.26M 94.61M
Interest expense 0.00M 22.82M 65.06M 23.77M 0.00M
Tax provision 0.06M 0.41M 0.34M -0.29M 0.08M
Interest income - 1.06M 2.25M 1.88M 0.43M
Net interest income - 1.06M 2.25M 1.88M 0.43M
Income tax expense 0.06M 0.41M 0.34M -0.29M 0.08M
Total revenue 180.96M 137.93M 108.09M 85.54M 66.64M
Total operating expenses 247.84M 177.06M 124.39M 87.81M 70.91M
Cost of revenue 79.93M 72.31M 44.62M 36.45M 23.70M
Total other income expense net -0.00M 10.63M 34.62M 12.74M -0.81M
Net income from continuing ops -149.19M -101.22M -26.64M -25.68M -28.43M
Net income applicable to common shares -149.19M -100.39M -24.46M -24.57M -28.43M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 802.96M 688.59M 756.49M 746.26M 155.27M
Intangible assets - 0.59M - - -
Other current assets 9.93M 26.95M 16.84M 8.86M 6.97M
Total liab 254.40M 240.68M 199.40M 122.24M 248.59M
Total stockholder equity 548.56M 447.89M 557.07M 624.01M -93.36M
Deferred long term liab - - 30.06M 41.16M -
Other current liab 43.76M 30.39M 25.72M 14.86M 10.86M
Common stock 0.72M 0.71M 0.71M 0.70M 0.06M
Capital stock 0.72M 0.71M 0.71M 0.70M 0.06M
Retained earnings -338.42M -379.14M -229.95M -129.56M -105.10M
Other liab - 26.40M 30.36M 41.82M 3.10M
Good will 4.79M 4.79M - - -
Other assets - 3.31M 2.85M 2.35M 2.34M
Cash 161.07M 90.47M 120.27M 202.30M 25.99M
Total current liabilities 133.67M 108.80M 91.21M 73.20M 45.02M
Current deferred revenue 56.23M 57.93M 55.37M 45.40M 25.05M
Net debt -33.18M 26.02M -40.40M -190.53M -11.51M
Short term debt 16.87M 11.01M 2.04M 4.54M 5.58M
Short long term debt total 127.88M 116.49M 79.87M 11.76M 14.47M
Other stockholder equity 885.97M 828.70M 786.96M 6.29M -179.93M
Property plant equipment - 120.23M 10.03M 5.14M 19.03M
Total current assets 567.80M 533.99M 625.06M 682.98M 118.54M
Long term investments 83.25M 25.68M 43.17M 45.66M 15.37M
Net tangible assets - 442.52M 557.07M 624.01M -93.36M
Short term investments 307.69M 360.61M 456.21M 440.39M 59.84M
Net receivables 89.12M 69.09M 40.55M 35.38M 25.74M
Inventory - -13.14M -8.81M -3.96M -
Accounts payable 16.82M 9.47M 8.08M 8.40M 3.52M
Noncontrolling interest in consolidated entity - - 0.01M 0.00M -
Accumulated other comprehensive income 0.28M -2.38M -0.65M 0.32M 0.02M
Common stock total equity - - 0.71M 0.70M 0.06M
Retained earnings total equity - - -229.95M -129.56M -
Non currrent assets other 6.01M 3.31M 2.85M 2.35M 2.34M
Non current assets total 235.16M 154.60M 131.43M 63.28M 36.73M
Capital lease obligations 127.88M 116.49M 79.87M 11.76M 14.47M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 90.02M -9.64M -379.18M -53.85M 11.19M
Change to liabilities -0.72M 8.46M 68.34M 6.42M 8.41M
Total cashflows from investing activities 90.02M -16.81M -381.72M -53.85M 11.19M
Total cash from financing activities 2.11M 7.95M 541.27M 28.68M 80.27M
Change to operating activities 7.30M 11.62M 3.87M 4.47M -3.86M
Net income -149.19M -101.22M -26.64M -25.68M -28.43M
Change in cash -27.55M -79.53M 176.31M -51.23M 67.76M
Begin period cash flow 123.27M 202.80M 26.49M 77.72M 9.96M
End period cash flow 95.72M 123.27M 202.80M 26.49M 77.72M
Total cash from operating activities -119.68M -70.67M 16.76M -26.06M -23.71M
Issuance of capital stock 0.00M 0.00M 537.09M 30.44M 80.27M
Depreciation 4.34M 2.85M 3.66M 3.64M 2.89M
Other cashflows from investing activities - - - -52.02M 16.45M
Change to inventory - 6.44M 7.34M 2.91M -3.86M
Change to account receivables -23.70M -0.32M -12.75M -5.04M -4.27M
Sale purchase of stock - 7.95M 215.67M 30.44M 80.27M
Other cashflows from financing activities 90.02M 7.95M 4.18M 28.14M 79.38M
Change to netincome 46.53M 28.41M 6.44M -9.42M 1.53M
Capital expenditures 8.01M 7.17M 2.54M 1.84M 5.26M
Change receivables - -0.32M -12.75M - -
Cash flows other operating - -8.84M -22.30M - -
Cash and cash equivalents changes - -79.53M 176.31M - -
Change in working capital -21.38M 4.68M 59.18M 4.29M 0.28M
Stock based compensation 39.63M 26.49M 10.54M 2.19M 1.31M
Other non cash items 6.91M 0.81M 2.14M 1.05M -0.15M
Free cash flow -127.70M -77.84M 14.22M -27.89M -28.97M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SDGR
Schrodinger Inc
1.58
6.16%
27.24 - - 8.83 3.49 7.28 -9.18
VEEV
Veeva Systems Inc Class A
-
-%
277.20 43.49 29.59 12.48 5.79 10.39 33.41
PMCUF
Pro Medicus Limited
-5.45
3.99%
131.10 64.90 90.91 49.11 38.05 65.12 83.47
TEM
Tempus AI, Inc. Class A Common Stock
0.19
0.30%
63.62 - - 8.68 25.39 8.33 -
MTHRY
M3 Inc
-0.18
3.24%
5.38 31.84 26.25 0.05 4.60 0.04 0.12

Profile*

Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

1540 Broadway, New York, NY, United States, 10036

212 295 5800

867

Name Title Year Born
Dr. Ramy Farid Ph.D. CEO, Pres & Director 1964
Dr. Richard A. Friesner Ph.D. Co-Founder, Scientific Advisory Chairman and Director 1953
Mr. Kenneth Patrick Lorton Exec. VP & CTO 1984
Dr. Robert Lorne Abel Ph.D. Exec. VP, Chief Computational Scientist and Head of Modeling R&D 1982
Dr. Karen Akinsanya Ph.D. Pres of R&D Therapeutics 1968
Prof. William Goddard III Co-Founder & Scientific Advisor NA
Dr. Geoffrey Craig Porges MBBS Exec. VP & CFO NA
Mr. Shane Brauner Exec. VP & Chief Information Officer 1978
Ms. Jaren Irene Madden Sr. VP of Investor Relations & Corp. Communications NA
Ms. Yvonne Tran Esq. Exec. VP, Chief Legal Officer & Sec. 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…